Advertisement
Advertisement
LGND
Ligand Pharmaceuticals Inc.
220.48
USDSponsored
-0.93
-0.42%
May 11, 15:59 UTC -4
Closed
Pre-Market
220.48
0.00
0.00%
LGND Earnings Reports
Positive Surprise Ratio
LGND beat 37 of 41 last estimates.
90%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$65.15M
/$2.06
Implied change from Q1 26 (Revenue/ EPS)
+25.96%
/+26.38%
Implied change from Q2 25 (Revenue/ EPS)
+36.79%
/+28.75%
Ligand Pharmaceuticals Inc. earnings per share and revenue
On May 07, 2026, LGND reported earnings of 1.63 USD per share (EPS) for Q1 26, missing the estimate of 1.85 USD, resulting in a -11.99% surprise. Revenue reached 51.72 million, compared to an expected 59.87 million, with a -13.61% difference. The market reacted with a -9.55% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of 2.06 USD, with revenue projected to reach 65.15 million USD, implying an increase of 26.38% EPS, and increase of 25.96% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Erasca, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+48.38%
Legend Biotech Corporation - ADR
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.15
Surprise
-597.67%
Oculis Holding AG Ordinary shares
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.42
Actual
-$0.49
Surprise
-15.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.52
Surprise
+3.60%
Certara, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
$0.10
Actual
$0.09
Surprise
-17.36%
Arvinas, Inc
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.93
Actual
-$0.90
Surprise
+4.00%
Tenax Therapeutics, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.35
Surprise
+14.22%
SAB Biotherapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-50.28%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.41
Actual
-$0.33
Surprise
+19.67%
Imunon, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$1.13
Actual
-$0.84
Surprise
+25.81%
FAQ
What were Ligand Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ligand Pharmaceuticals Inc. reported EPS of $1.63, missing estimates by -11.99%, and revenue of $51.72M, -13.61% below expectations.
How did the market react to Ligand Pharmaceuticals Inc.'s Q1 2026 earnings?
The stock price moved down -9.55%, changed from $232.55 before the earnings release to $210.33 the day after.
When is Ligand Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Ligand Pharmaceuticals Inc.'s next earnings report?
Based on 5
analysts, Ligand Pharmaceuticals Inc. is expected to report EPS of $2.06 and revenue of $65.15M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement